Zobrazeno 1 - 10
of 116
pro vyhledávání: '"Louis M. Staudt"'
Autor:
John Gerecitano, Jodi Carey, Christopher Major, Peter Johnson, Songbai Wang, Pier Luigi Zinzani, Wyndham H. Wilson, Steven Sun, Jessica Vermeulen, S. Martin Shreeve, Louis M. Staudt, Laurie H. Sehn, Michael Schaffer, Brendan P. Hodkinson, Sriram Balasubramanian
Publikováno v:
Br J Haematol
We assessed the concordance between immunohistochemistry (IHC) and gene expression profiling (GEP) for determining diffuse large B-cell lymphoma (DLBCL) cell of origin (COO) in the phase III PHOENIX trial of rituximab plus cyclophosphamide, doxorubic
Autor:
Brendan Hodkinson, Louis M. Staudt, George E. Wright, Martin Shreeve, Sriram Balasubramanian, Yue Fan, Wyndham H. Wilson, Da-Wei Huang, Jessica Vermeulen
Publikováno v:
Cancer cell. 39(12)
Summary In diffuse large B cell lymphoma (DLBCL), tumors belonging to the ABC but not GCB gene expression subgroup rely upon chronic active B cell receptor signaling for viability, a dependency that is targetable by ibrutinib. A phase III trial (“P
Autor:
Miguel Alcaide, Christopher Rushton, Laura K. Hilton, Adele Telenius, Anja Mottok, Jie Gao, Shannon Healy, Daniel J. Hodson, Nicole Thomas, Louis M. Staudt, Jeffrey Tang, Kostiantyn Dreval, Wyndham H. Wilson, Peter J. Unrau, Razvan Cojocaru, David Scott, Ryan D. Morin, Christian Steidl, Sarah E. Arthur
Amplifications and non-coding 3′ UTR mutations affecting NFKBIZ have been identified as recurrent genetic events in diffuse large B-cell lymphoma (DLBCL). We confirm the prevalence and pattern of NFKBIZ 3′ UTR mutations in independent cohorts and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a520142c4b4ac211f7f38619dd526570
https://doi.org/10.1101/2021.05.22.445261
https://doi.org/10.1101/2021.05.22.445261
Autor:
Louis M. Staudt, Amy S. Kimball, Sven de Vos, Jerry Ping, Darrin M. Beaupre, Wyndham H. Wilson, Da-Wei Huang, Kevin A. Kwei, George E. Wright, Leslie Popplewell, Jutta K. Neuenburg, Saurabh Chhabra, Tycel Phillips
Publikováno v:
Leukemialymphoma. 62(9)
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is difficult to cure; non-germinal center B-cell-like (non-GCB) and activated B-cell-like (ABC) DLBCL have worse outcomes than GCB DLBCL. Ibrutinib and lenalidomide are synergistic in vitro in
Autor:
Jeremy S. Abramson, Heiko Schöder, Wyndham H. Wilson, Richard I. Fisher, Nancy L. Bartlett, Matthew J. Maurer, Levi Pederson, John P. Leonard, Jane N. Winter, Nishitha Reddy, Louis M. Staudt, Nina D. Wagner-Johnston, Kristie A. Blum, Susan Mathew, Julie E. Chang, Ajay K. Gopal, Jonathan W. Friedberg, Brad S. Kahl, Amy Chadburn, Kristy L. Richards, Brandelyn N. Pitcher, Bruce D. Cheson, Mei Yin C. Polley, Andrew D. Zelenetz, Eric D. Hsi, Sin-Ho Jung
Publikováno v:
Journal of Clinical Oncology. 37:1790-1799
PURPOSE Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study, compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard rituximab, cyclophosphamide, doxorubicin, v
Autor:
Sirpa Leppä, Su-Peng Yeh, Ronit Gurion, Mehmet Turgut, Sriram Balasubramanian, Laurie H. Sehn, Anas Younes, Sen Hong Zhuang, Xiaonan Hong, Pier Luigi Zinzani, Andres Lopez-Hernandez, Shinya Rai, Caterina Patti, S. Martin Shreeve, Wojciech Jurczak, David Belada, Matthew C. Cheung, Olga Samoilova, Cheolwon Suh, Jessica Vermeulen, Louis M. Staudt, Jodi Carey, Catherine Thieblemont, Peter Johnson, C.S. Chiattone, Ulrich Dührsen, Grace Liu, Wyndham H. Wilson, Steven Sun, Jun Zhu
Publikováno v:
Journal of Clinical Oncology. 37:1285-1295
60th Annual Meeting of the American-Society-of-Hematology (ASH) -- DEC 01-04, 2018 -- San Diego, CA Jurczak, Wojciech/0000-0003-1879-8084; Johnson, Peter/0000-0003-2306-4974; ZINZANI, PIER LUIGI/0000-0002-2112-2651; Leppa, Sirpa/0000-0002-8265-511X W
Autor:
Louis M. Staudt, Roland Schmitz, Thomas Oellerich, Wyndham H. Wilson, George E. Wright, Ryan M. Young, James D. Phelan, Calvin A. Johnson, Arthur L. Shaffer, Da-Wei Huang
Publikováno v:
Annual Review of Cancer Biology. 3:429-455
Genomic analyses of diffuse large B cell lymphoma (DLBCL) are revealing the genetic and phenotypic heterogeneity of these aggressive lymphomas. In part, this heterogeneity reflects the existence of distinct genetic subtypes that acquire characteristi
Autor:
George E. Wright, Louis M. Staudt, Thomas Oellerich, Björn Häupl, Xin Yu, Da-Wei Huang, Zhuo Wang, Arthur L. Shaffer, James D. Phelan, Hong Zhao, Jaewoo Choi, Ryan M. Young
Publikováno v:
Proc Natl Acad Sci U S A
The KLHL14 gene acquires frequent inactivating mutations in mature B cell malignancies, especially in the MYD88 L265P , CD79B mutant (MCD) genetic subtype of diffuse large B cell lymphoma (DLBCL), which relies on B cell receptor (BCR) signaling for s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3035e84997241bf126f15b340b268f1
https://europepmc.org/articles/PMC7084139/
https://europepmc.org/articles/PMC7084139/
Autor:
Christopher Major, Louis M. Staudt, P. Johnson, Brendan P. Hodkinson, Jessica Vermeulen, Jodi Carey, Michael Schaffer, M. Shreeve, Shean-Sheng Wang, Walter R. Wilson, Anas Younes, Steven Sun, Grace Liu, C. Loefgren, P. L. Zinzani, Laurie H. Sehn, Sen Hong Zhuang, Sriram Balasubramanian
Publikováno v:
Hematological Oncology. 37:140-142
Publikováno v:
Oncotarget
// Georgios N. Pongas 1,2,3 , Christina M. Annunziata 2,3 and Louis M. Staudt 1 1 Lymphoid Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA 2 Medical Oncology Service, National Cancer Institute, Nationa